Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

Siegel CA, Finlayson SR, Sands BE, Tosteson AN.

Clin Gastroenterol Hepatol. 2012 Jan;10(1):46-51. doi: 10.1016/j.cgh.2011.09.017. Epub 2011 Oct 1.

2.

Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.

Saito S, Shimizu U, Nan Z, Mandai N, Yokoyama J, Terajima K, Akazawa K.

J Crohns Colitis. 2013 Mar;7(2):167-74. doi: 10.1016/j.crohns.2012.04.007. Epub 2012 May 22.

PMID:
22626508
3.

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK.

Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067. doi: 10.1002/14651858.CD000067.pub3. Review.

PMID:
26517527
4.

A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.

Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1042-8. doi: 10.1097/MEG.0b013e32832937e3.

PMID:
20139856
5.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.

Gut. 2007 Sep;56(9):1226-31. Epub 2007 Jan 17.

6.

The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

Scott FI, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, Lewis JD.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):302-309.e11. doi: 10.1016/j.cgh.2014.07.058. Epub 2014 Aug 10.

7.

Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P.

Aliment Pharmacol Ther. 2016 Nov;44(10):1102-1113. doi: 10.1111/apt.13808. Epub 2016 Sep 26.

PMID:
27666569
8.

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.

Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ.

Aliment Pharmacol Ther. 2015 Apr;41(8):734-46. doi: 10.1111/apt.13139. Epub 2015 Mar 1.

9.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.

Cochrane Database Syst Rev. 2014 Aug 6;(8):CD003459. doi: 10.1002/14651858.CD003459.pub4. Review.

PMID:
25099640
10.

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P.

Gastroenterology. 2008 Jun;134(7):1861-8. doi: 10.1053/j.gastro.2008.03.004. Epub 2008 Mar 8.

PMID:
18440315
11.

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR.

Am J Gastroenterol. 2011 Nov;106(11):2009-17. doi: 10.1038/ajg.2011.237. Epub 2011 Jul 26.

PMID:
21788991
12.

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.

Zhang T, Wang Z, Fan R, Zhang M, Lin Y, Hong L, Zhou X, Hu S, Cheng M, Zhong J.

Biomed Res Int. 2016;2016:8648307. Epub 2016 Nov 8.

13.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD003459.

PMID:
23235598
14.

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.

Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034. Epub 2015 Jun 30. Review.

PMID:
26142167
15.

Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.

Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC).

Clin Gastroenterol Hepatol. 2013 Jul;11(7):826-31. doi: 10.1016/j.cgh.2013.01.012. Epub 2013 Jan 29.

PMID:
23376000
16.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25.

PMID:
25066841
17.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Chande N, Tsoulis DJ, MacDonald JK.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD000545. doi: 10.1002/14651858.CD000545.pub4. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 26;10 :CD000545.

PMID:
23633304
18.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Chande N, Townsend CM, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2016 Oct 26;10:CD000545. Review.

PMID:
27783843
19.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
20.

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE.

Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. Epub 2006 Jul 14.

PMID:
16843733

Supplemental Content

Support Center